View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
July 27, 2018

NeuroVia starts Phase l/ll trial of NV1205 for CCALD

NeuroVia has commenced a Phase l/ll clinical trial of NV1205 for the treatment of patients with childhood cerebral adrenoleukodystrophy (CCALD).

NeuroVia has commenced a Phase l/ll clinical trial of NV1205 for the treatment of patients with childhood cerebral adrenoleukodystrophy (CCALD).

The trial aims to evaluate the safety, tolerability and pharmacokinetics of increasing doses of NV1205 in patients diagnosed with CCALD.

The trial is to be conducted in eight different countries, including Argentina, Australia, Chile, Colombia, France, the Russian Federation, Ukraine and the UK, and estimated to enrol 25 subjects.

It will include a 30-day screening period starting from the administration of the first dose.

It will also feature a main treatment period of 12 weeks, where subjects will have an initial four-week treatment period at the assigned dose and, if no safety concerns are noted, subjects will continue for another eight weeks of extended safety assessment.

A long-term treatment (LTT) period is also included in the trial to allow the subjects to continue to receive treatment.

“We believe NV1205 has real potential to better serve the X-ALD community as a novel, pharmaceutical treatment for all X-ALD patients.”

The primary endpoint of the trial is the number of participants with treatment-related adverse events as assessed by common terminology criteria for adverse events v4.0 (CTCAE v4.0) over a period of two years.

The trial’s secondary endpoints include area under the curve concentration of NV1205 in plasma over a 12-week period, among others.

It will further evaluate percentage change from baseline in brain lesions assessed as Loes score.

NeuroVia chief development officer John Henderson said: “The study initiation in Australia, Chile and the UK is just the first step in our global clinical development strategy.

“We believe NV1205 has real potential to better serve the X-ALD community as a novel, pharmaceutical treatment for all X-ALD patients.”

NV1205 is an investigational synthetic small molecule designed to restore metabolic activity within the cells by allowing them to process the detrimental, accumulating very long chain fatty acids (VLCFA) and avoid the resulting damage to neuronal and mitochondrial membranes altogether.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU